0001628280-26-024943
SEC filingVistaGen Therapeutics' Compensation Committee approved retention stock options for all employees, including five key executives each receiving options for 75,000 shares at $0.5358 per share, vesting over two years.
The retention awards, approved by the Compensation Committee in consultation with an independent consultant, signal the board's focus on retaining executive leadership during a potentially critical period for VistaGen Therapeutics. Each of the five named executives—covering CEO, CFO, COO, Chief Legal Officer, and Chief Corporate Development Officer—received identical grants of 75,000 options, promoting alignment with shareholder interests through equity incentives tied to the common stock's performance. The two-year cliff vesting structure encourages sustained commitment, with no cash outlay required from the company, preserving liquidity while linking executive rewards to long-term value creation.